Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Harlan Laboratories and Fluofarma, a French contract research organization (CRO), have entered into a strategic partnership to strengthen the companies' drug discovery and translational medicine services.
Subscribe to our email newsletter
Harlan provides general and specialty toxicology services through its Contract Research Services (CRS) business.
Under the deal, Harlan CRS will use Fluofarma’s expertise in high content analysis, biomarkers quantification and high content histology, including applications to mechanistic toxicology and prediction of toxicity.
Harlan CRS director of strategic initiatives and director of drug discovery and translational medicine Ciriaco Maraschiello said: "This alliance with Fluofarma enables us to strengthen our services during the early stages of development so that we can be a key partner for our customers."
Fluofarma CEO Jean-Baptiste Pin said the agreement will be a tremendous growth accelerator for the company by improving its international visibility.
"For us, it’s the confirmation that our high content analysis technologies and translational research skills can add value to the global drug development process," Pin said.
Fluofarma develops cell- and tissue-based assays for preclinical and clinical drug discovery by using High-Content Analysis (HCA) technologies.